Impact of age on extra-fine particle hydrofluoroalkane beclometasone dipropionate versus fluticasone propionate outcomes in asthmatic children
W. van Aalderen, D. Price, G. Colice, P. Dorinsky, E. Israel, R. Martin, D. Postma, N. Roche, A. Burden, E. Hillyer, C. Hutton, J. von Ziegenweidt, J. Grigg (Amsterdam, Groningen, Netherlands; Aberdeen, Cambridge, London, United Kingdom; Washington, Morrisville, Boston, Denver, United States Of America; Paris, France)
Source: Annual Congress 2013 –Treatment and management of asthma in primary care
Session: Treatment and management of asthma in primary care
Session type: Thematic Poster Session
Number: 3825
Disease area: Airway diseases, Paediatric lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
W. van Aalderen, D. Price, G. Colice, P. Dorinsky, E. Israel, R. Martin, D. Postma, N. Roche, A. Burden, E. Hillyer, C. Hutton, J. von Ziegenweidt, J. Grigg (Amsterdam, Groningen, Netherlands; Aberdeen, Cambridge, London, United Kingdom; Washington, Morrisville, Boston, Denver, United States Of America; Paris, France). Impact of age on extra-fine particle hydrofluoroalkane beclometasone dipropionate versus fluticasone propionate outcomes in asthmatic children. Eur Respir J 2013; 42: Suppl. 57, 3825
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Comparative effectiveness analysis: Extra-fine particle hydrofluoroalkane beclomethasone dipropionate vs fluticasone propionate with spacer in children Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013
Pharmacokinetic and pharmacodynamic evaluation after administration of beclomethasone dipropionate and formoterol fumarate as fixed or free metered-dose inhaler combination in adolescent asthma Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013
HFA beclomethasone dipropionate (HFA-BDP) extrafine aerosol and formoterol in optimizing the management of bronchial asthma at children Source: Eur Respir J 2005; 26: Suppl. 49, 159s Year: 2005
Health related quality of life evaluation after beclomethasone dipropionate (BDP) treatment in children with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 381s Year: 2004
Plume characteristics of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013
Comparative efficacy and costs of the treatment of moderate to severe persistent asthma with a new dry-powder inhaled beclomethasone dipropionate and formoterol combination Source: Annual Congress 2013 –Health economics of airway diseases Year: 2013
Effects of the changing from chlorofluorocarbon (CFC)- beclomethasone dipropionate (BDP) to hydrofluoroalkane (HFA)-BDP on pulmonary function in asthmatic children Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma Year: 2007
No age effect on systemic exposure to beclometasone and formoterol after pressurized metered dose inhalation in paediatric, adolescent and adult asthma Source: Annual Congress 2013 –Uncontrolled and severe asthma in children Year: 2013
Acceptability and efficacy of beclomethasone dipropionate (Béclojet HFA®) and fluticasone dipropionate (Flixotide HFA®, FDP) associated with the Volumatic® spacer in adults with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 473s Year: 2003
Efficacy of salmeterol/fluticasone propionate (50/100mcg/day) delivered via the Diskus™ and MDI in children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 311s Year: 2003
Plume temperature and force of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014
A pharmaco-epidemiological audit of beclomethasone dipropionate extrafine aerosol in patients with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 471s Year: 2002
Safety profile of ciclesonide as compared with fluticasone propionate in the treatment of children and adolescents with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 346s Year: 2004
QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009
Late Breaking Abstract - Comparing pneumonia risk in COPD patients initiating Fixed Dose Combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus fluticasone Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data Year: 2021
HFA vs CFC beclomethasone dipropionate – comparative effectiveness in asthma management Source: Eur Respir J 2006; 28: Suppl. 50, 498s Year: 2006
Dose-proportional lung bioavailability of beclometasone dipropionate and formoterol fumarate across three different dose strenghts of CHF1535 pMDI Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Comparison of a new extrafine beclomethasone dipropionate HFA134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006
Efficacy, safety and cost of using beclomethason dipropionate in patients with persistent moderate bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 124s Year: 2004
Achievement of total control of asthma in clinical practice using the combination of inhaled salmeterol and fluticasone propionate Source: Eur Respir J 2006; 28: Suppl. 50, 616s Year: 2006